FIELD: medicine; pharmaceuticals; food industry.
SUBSTANCE: invention relates to a method of correcting the functional state of TK2-associated mitochondrial myopathy. A method of correcting the functional state of TK2-associated mitochondrial myopathy, including oral administration from one to five times a day of a combined medical nutrition product, which includes thymidine and deoxycytidine, each in an amount from 200 to 800 mg and maltodextrin in an amount from 69 to 276 mg, or a combined therapeutic nutrition product, including two separate compositions, with composition 1 containing thymidine in an amount from 200 to 400 mg and maltodextrin in an amount from 69 to 139 mg, composition 2 containing deoxycytidine in an amount from 200 to 400 mg and maltodextrin in an amount from 69 up to 139 mg. The above-described method of correcting the functional state ensures the absence of undesirable events and undesirable reactions, such as deviations from the norm in biochemical indicators of the condition of the liver and kidneys; no diarrhea; the presence of statistically significant differences in the average score of the HFMSE scale, reflecting gross motor skills; statistically significant differences in the average score of all indicators of the HINE-2 Scale; statistically significant differences in the average score of the MRC Scale, which reflects muscle strength; differences in the average need for respiratory support (NIV) before and field of product use, compared with the use of deoxynucleosides in the form of chemicals. The product also has good organoleptic properties and a pleasant taste.
EFFECT: obtaining a method of correcting the functional state of TK2-associated mitochondrial myopathy.
4 cl, 13 tbl, 1 ex
